Related Experiment Videos
Intranasally administered immunoglobulin for the prevention of rhinitis in children
T Heikkinen1, A Ruohola, O Ruuskanen
1Department of Pediatrics, University of Turku, Finland.
Insights
Intranasal immunoglobulin significantly reduced rhinitis symptoms in young children attending daycare. This treatment offers a promising approach for preventing common respiratory infections in pediatric populations.
Area of Science:
- Pediatrics
- Immunology
- Respiratory Medicine
Background:
- Rhinitis is a common condition in children, particularly those attending daycare.
- Effective preventative strategies for pediatric rhinitis are needed.
Purpose of the Study:
- To evaluate the efficacy of intranasal immunoglobulin in preventing rhinitis symptoms in children aged 1-4 years.
Main Methods:
- A double-blind, placebo-controlled study involving 40 children.
- Children received either immunoglobulin A nasal spray or placebo twice daily for 8 weeks.
- Parental daily symptom recording and an 8-week follow-up period.
Main Results:
- The immunoglobulin group experienced 42% fewer rhinitis days compared to placebo (10.8 vs. 18.7 days, P=0.004).
- Fewer total episodes of rhinitis were observed in the immunoglobulin group (33 vs. 51).
- No significant differences were noted during the post-medication follow-up period.
Conclusions:
- Intranasal immunoglobulin is effective in preventing rhinitis symptoms in children.
- Further research is warranted to explore this preventative method.
Objective:
To determine the efficacy of intranasally administered immunoglobulin in preventing symptoms of rhinitis in children.
Methods:
Forty children ages 1 to 4 years who attended day-care centers in Turku, Finland, were enrolled in the double blind, placebo-controlled study. The children were randomly assigned to receive treatment with immunoglobulin, composed mainly of immunoglobulin A, or placebo, both administered as nasal sprays twice daily for 8 weeks. During this medication period and an additional 8-week follow-up period, the parents recorded the symptoms of the children daily in the diaries provided. One child who met an exclusion criterion was withdrawn from the study after a few days of medication.
Results:
During the 8-week medication period the 19 children in the immunoglobulin group had 42% fewer days with rhinitis than the 20 children receiving placebo (mean, 10.8 vs. 18.7 days; P=0.004). The total numbers of episodes of rhinitis in the immunoglobulin and placebo groups were 33 and 51, respectively. No significant differences were observed between the groups during the postmedication follow-up period.
Conclusions:
Intranasal administration of immunoglobulin appears to be an effective method to prevent symptoms of rhinitis in children, and further studies of this approach are needed.